BPC-157 and Nasal Delivery Despite mounting research on nasal peptide administration, studies on nasal delivery of BPC-157 are lacking
The second is that Canadas formulary, at least in Ontario and Nova Scotia, is restrictive, meaning that as a general principle, Canada is willing to trade options for savings
Therefore, a new drug that simultaneously coactivates both the glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R) has been developed
This review aims to systematically summarize the mechanistic insights and clinical advances of GLP-1with dual or triple receptor agonists in MASLD treatment, thereby promoting a more profound comprehension and facilitating their application in clinical practice (Figure 1)
doi: 10.1186/s13063-016-1324-2
At least three daily measurements of capillary blood glucose are recommended